FRAX - modell för att beräkna 10-årsrisken för fraktur

Lakartidningen

Volumn 108, Issue 7, 2011, Pages 336-339

  Johansson, Helena ^a   Kanis, John A ^b   Ljunggren, Östen ^c   Ström, Oskar ^d   Svensson, Olle ^e   Mellström, Dan ^f  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; BONE DENSITY; DECISION SUPPORT SYSTEM; FEMALE; FRAGILITY FRACTURE; HUMAN; INCIDENCE; INTERNET; MALE; METHODOLOGY; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SWEDEN; WORLD HEALTH ORGANIZATION;

ALGORITHMS; BONE DENSITY; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; INCIDENCE; INTERNET; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SWEDEN; WORLD HEALTH ORGANIZATION;

EID: 79951647675     PISSN: 00237205     EISSN: 16527518     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sjöberg C, Bladh L, Klintberg L, Mellström D, Ohlsson C, Wallerstedt SM. Treatment with fallrisk-increasing and fracture-preventing drugs before and after a hip fracture: an observational study. Drugs Aging. 2010;27(8): 653-61.
2. Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009;44 (5):734-43.
3. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18 (8):1033-46.
4. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-97.
5. World Health Organization. Assessment of osteoporosis at the primary health care level. Geneva: WHO; 2007.
6. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res. 2002;17(7):1237-44.
7. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000;11(8):669-74.
8. Dawson-Hughes B. A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab. 2008;93 (7):2463-5.
9. Kanis JA, McCloskey EV, Johansson H, Ström O, Borgström F, Oden A. Case finding for the management of osteoporosis with FRAX - assessment and intervention thresholds for the UK. Osteoporos Int. 2008;19(10):1395-408.
10. De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11):1330-8.
11. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8(5): 468-89.
12. Johansson H, Oden A, Johnell O, Jonsson B, de Laet C, Oglesby A, et al. Optimization of BMD measurements to identify high risk groups for treatment - a test analysis. J Bone Miner Res. 2004;19(6):906-13.
13. Kanis JA, Johnell O, Oden A, Borgström F, Johansson H, De Laet C, et al. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int. 2005;16(1):6-14.
14. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383-9.
15. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int. 2005; 16(7):737-42.
16. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16(2):155-62.
17. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone. 2003;33(4):522-32.
18. Lunt M, O'Neill TW, Felsenberg D, Reeve J, Kanis JA, Cooper C, et al. Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone. 2003;33(4):505-13.
19. McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy - additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int. 2009;20 (5):811-7.
20. Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009;44(6):1049-54.